Welcome, fellow investors! Today, we’re diving deep into the world of Johnson & Johnson (JNJ), a pharmaceutical giant with a substantial $491.26 billion market capitalization. As a prominent player in the Drug Manufacturers – General industry, JNJ often sparks questions about its current valuation and future growth prospects. Is now the right moment to consider adding JNJ to your portfolio?
That’s precisely what we’re here to figure out. We’ll explore JNJ’s performance in the current market, dissect its financials, and look at what the experts are saying. My goal is to equip you with clear, actionable insights, regardless of whether you’re a long-term growth investor or someone looking for shorter-term opportunities.
JNJ Stock: What You Need to Know Right Now
As of November 2025, JNJ stock is trading at $203.90. It’s showing some impressive positive momentum, comfortably positioned above both its 50-day and 200-day moving averages. This often signals a healthy uptrend to many technical analysts.
However, it’s not all smooth sailing. Analysts have set a 1-year price target of $200.82, which suggests a potential -6.2% downside from the current price. We’re also looking at significant annualized volatility of 14.2%, meaning JNJ’s price can swing quite a bit.
Fundamentally, Johnson & Johnson presents a mixed picture. The company boasts solid revenue growth, up 6.80% year-over-year. But it also operates in an incredibly competitive sector, which always brings its own set of challenges. It’s a dynamic environment, and understanding these nuances is key.
What’s Inside This Comprehensive JNJ Stock Analysis?
This isn’t just a basic overview; we’re breaking down JNJ from every possible angle to help you make a truly informed investment decision. Here’s what we’ll cover:
- Is now a good time to buy JNJ? Technically, things look neutral, but the Relative Strength Index (RSI) is flashing an overbought signal at 100.0. Fundamentally, the company appears solid, supported by its debt levels and growth metrics.
- Can JNJ’s core operations drive future growth? The future largely depends on how well its Drug Manufacturers – General segment performs and its ability to navigate intense competitive pressures.
- What are the biggest risks for JNJ investors? Johnson & Johnson carries a substantial $45.80 billion in debt, which could be a concern in a rising interest rate environment. Plus, competition from both established players and new innovators is fierce.
Forget the overly complicated jargon or the simplistic “just buy” advice. Our aim is to provide you with clear, digestible information. By the end of this analysis, you’ll have a much clearer picture of whether Johnson & Johnson aligns with your investment goals. So, let’s dig into the data!
Key JNJ Metrics and Forecast Summary
Let’s start with a snapshot of Johnson & Johnson’s current standing, including its live market price and crucial forecasts.
| Metric Category | Metric | Value | Details/Change |
|---|---|---|---|
| Current Price | Live Market Price | $203.90 | (as of November 2025) |
| Price Targets & Forecasts | 1-Month Forecast | $203.90 | -0.0% |
| 1-Year Forecast | $191.21 | -6.2% potential downside | |
| Analyst Mean Target | $200.82 | -1.5% potential downside | |
| Trend & Momentum | Trend | Bullish | Price > SMA 50/200 |
| RSI (14-day) | 100.0 | Overbought 🔥 | |
| MACD | Bullish Short-Term Trend | 1.28 | |
| Key Technical Levels | Above SMA 50 | $191.54 | ✅ |
| Above SMA 200 | $170.68 | ✅ | |
| 52-Week Range | $140.68 – $206.94 | ||
| Volatility | Volatility (30d Ann.) | 14.2% | Moderate |
| Beta (vs. Market) | 0.36x | Low Sensitivity | |
| Ownership & Short Interest | Institutional Ownership | 74.93% | Strong institutional backing |
| Short % of Float | 0.81% | Low bearish bets |
Currently, JNJ’s stock is trading at $203.90. The technical picture is looking quite bullish because the price is holding strong above both its 50-day ($191.54) and 200-day ($170.68) moving averages. This indicates the stock has been building momentum.
However, there’s a significant caution flag: the 14-day Relative Strength Index (RSI) is at 100.0, which is a clear overbought signal. While the MACD indicator points to a bullish short-term trend, that high RSI suggests we might see some minor pullbacks before the next potential upward move. It’s a classic sign to be wary of chasing the price too aggressively.
Over the past year, JNJ has traded within a range of $140.68 to $206.94. This tells us two important things: first, the stock has made a substantial recovery from its lows. Second, the current price is near the higher end of this range, meaning major upward swings might be less likely without significant new catalysts.
Analysts are anticipating modest growth, with a 1-year target of $191.21 (a potential -6.2% change) and a consensus target of $200.82 (a -1.5% change). What’s interesting is the substantial 74.93% institutional ownership combined with a very low short interest of 0.81%. This suggests that large investors are largely confident in JNJ’s long-term success rather than betting against it.
Detailed JNJ Forecast Table (2025-2026)
Let’s look at the projected price movements for JNJ over the next year, from November 2025 to November 2026. The model suggests an overall price range of approximately $167.59 to $205.99. It’s important to remember these are model-based estimates and not guarantees.
| Month (Period) | Min. Price | Avg. Price | Max. Price | Potential ROI vs Current ($203.90) | Model Signal |
|---|---|---|---|---|---|
| 2025-11 | $203.90 | $203.90 | $203.90 | -0.0% | Hold/Neutral |
| 2025-12 | $167.59 | $176.01 | $186.33 | -13.7% | Consider Short |
| 2026-01 | $168.00 | $177.71 | $189.88 | -12.8% | Consider Short |
| 2026-02 | $167.64 | $178.59 | $188.42 | -12.4% | Consider Short |
| 2026-03 | $168.10 | $178.95 | $191.13 | -12.2% | Consider Short |
| 2026-04 | $173.19 | $180.02 | $189.31 | -11.7% | Consider Short |
| 2026-05 | $171.78 | $181.35 | $191.95 | -11.1% | Consider Short |
| 2026-06 | $171.61 | $181.87 | $192.11 | -10.8% | Consider Short |
| 2026-07 | $170.66 | $183.56 | $194.01 | -10.0% | Consider Short |
| 2026-08 | $178.35 | $188.01 | $201.65 | -7.8% | Consider Short |
| 2026-09 | $181.25 | $191.21 | $202.04 | -6.2% | Consider Short |
| 2026-10 | $178.00 | $191.21 | $203.44 | -6.2% | Consider Short |
| 2026-11 | $179.52 | $191.96 | $205.99 | -5.9% | Consider Short |
As you can see, the model projects the average price to trend downwards over the next year, with signals leaning towards “Consider Short” for most periods after November 2025. The projected price range remains relatively consistent, suggesting that the model’s uncertainty about future price movements is stable. These forecasts are based on current data and can change quickly with market shifts.
Johnson & Johnson (JNJ) Company Profile
Before we dive deeper into the numbers, it’s essential to understand the company behind the ticker. Johnson & Johnson is a diversified healthcare giant with a rich history.
| Category | Detail |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers – General |
| Market Cap | $491.26 Billion |
| Employees | 138,100 |
| Website | https://www.jnj.com |
Johnson & Johnson (JNJ) Company Description
Johnson & Johnson, founded in 1886 and headquartered in New Brunswick, New Jersey, is a global powerhouse in the healthcare field. The company is actively involved in the research and development, manufacturing, and sale of a vast array of products worldwide. It operates primarily through two key segments: Innovative Medicine and MedTech.
The Innovative Medicine segment focuses on developing products across various therapeutic areas. This includes immunology, targeting conditions like rheumatoid arthritis and psoriasis; infectious diseases, such as HIV/AIDS; and neuroscience, addressing mood disorders and schizophrenia. Furthermore, this segment is active in oncology, cardiovascular and metabolism, and pulmonary hypertension, serving patients through a wide network of retailers, wholesalers, hospitals, and healthcare professionals.
Meanwhile, the MedTech segment provides advanced medical technologies. This encompasses electrophysiology products for heart rhythm disorders, and a heart recovery portfolio for severe coronary artery disease. It also includes circulatory restoration products for calcified coronary artery and peripheral artery diseases, and neurovascular care for stroke treatments. Additionally, MedTech offers an extensive orthopaedics portfolio (hips, knees, trauma, spine) and advanced surgery technologies. It’s also known for its ACUVUE contact lenses and TECNIS intraocular lenses for cataract surgery. The MedTech products are distributed to hospitals, retailers, and directly to physicians, nurses, and eye care professionals.
JNJ Total Valuation Analysis
When we look at Johnson & Johnson, the market clearly sees it as a critical player in the Drug Manufacturers – General industry. With a substantial market cap of $491.26 billion, it’s a heavyweight.
However, its enterprise value stands even higher at $518.49 billion, with $27.23 billion of that value attributable to debt. While investors generally show confidence in JNJ’s future earnings, it’s crucial to keep a close eye on that significant debt load, especially in a dynamic interest rate environment.
The company’s valuation ratios offer some interesting insights. Trading at 5.63x revenue and 16.24x EBITDA, JNJ commands a premium compared to many of its peers. This premium often reflects the company’s strong market position, its well-recognized brand assets, and its history of innovation. Yet, it also implies that the stock might have less room for error if growth expectations aren’t met.
The upcoming earnings report on January 21, 2026, will be a critical event. It will show whether JNJ’s diverse businesses can continue to grow into this robust valuation. Additionally, the November 25, 2025 ex-dividend date reminds us that Johnson & Johnson actively rewards its shareholders while simultaneously investing for future expansion. Essentially, with JNJ, you’re paying for quality, and quality rarely comes cheap.
| Metric | Value |
|---|---|
| Market Cap | $491.26 Billion |
| Enterprise Value | $518.49 Billion |
| EV/Revenue (TTM) | 5.63x |
| EV/EBITDA (TTM) | 16.24x |
| Next Earnings Date | 2026-01-21 |
| Ex-Dividend Date | 2025-11-25 |
JNJ Share Statistics & Ownership Insights
Let’s examine the structure of JNJ’s shares and who owns them, as this can tell us a lot about liquidity and market sentiment.
Nearly all of Johnson & Johnson’s 2 billion shares are publicly available as float, meaning there isn’t a significant amount locked up. A high float typically allows investors to trade the stock without causing drastic price shifts, which is good for liquidity. However, it’s always worth noting the potential for share dilution if the company decides to issue more shares in the future.
Interestingly, executive and major shareholder ownership is quite low at just 0.06%. This might suggest they don’t have substantial “skin in the game” if the company faces challenges. On the flip side, institutional ownership is very significant, coming in at 74.93%. This high level of institutional backing often provides a degree of stability and confidence in the stock, as large funds have done their extensive due diligence.
Now, let’s talk about short interest. With 20 million shares shorted, representing 0.81% of the float, it suggests that bearish sentiment isn’t particularly strong for JNJ. This low percentage indicates that a “short squeeze” (where short sellers are forced to buy back shares, driving the price up rapidly) is less likely. Investors should still monitor changes in short interest, as a sharp increase could signal growing doubt among some market participants.
| Metric | Value |
|---|---|
| Shares Outstanding | 2 Billion |
| Implied Shares Outstanding | 2 Billion |
| Shares Float | 2 Billion |
| Insider Ownership | 0.06% |
| Institutional Ownership | 74.93% |
| Shares Short | 20 Million |
| Short Ratio (Days To Cover) | 2.30x |
| Short % of Float | 0.81% |
| Shares Short (Prior Month) | 18 Million |
| Short Date | 2025-10-31 |
JNJ Valuation Metrics: A Deeper Dive
When we look at Johnson & Johnson’s valuation, several key ratios paint a detailed picture.
| Metric | Value |
|---|---|
| Trailing P/E | 19.68x |
| Forward P/E | 19.24x |
| Price/Sales (TTM) | $5.33 |
| Price/Book (MRQ) | $6.19 |
| EV/Revenue (TTM) | 5.63x |
| EV/EBITDA (TTM) | 16.24x |
JNJ’s Trailing P/E of 19.68x and a slightly lower Forward P/E of 19.24x suggest a reasonably valued company with modest expectations for future earnings improvement. These figures are important benchmarks for comparing JNJ against its industry peers.
Meanwhile, its Price/Sales ratio of $5.33 and Price/Book ratio of $6.19 indicate that the company trades at multiples that warrant attention. These metrics provide additional insight into how the market values JNJ’s sales and assets relative to its share price, often reflecting its strong brand equity and market position.
From an enterprise value perspective, the EV/Revenue ratio of 5.63x suggests a reasonable valuation when considering its revenue streams. However, the EV/EBITDA multiple of 16.24x might suggest a potentially stretched valuation. These enterprise valuation metrics offer a more comprehensive view, factoring in debt, which is crucial for a company of JNJ’s size.
JNJ Financial Health Assessment
Johnson & Johnson’s financial health appears quite robust, highlighting several core strengths that investors often look for.
| Metric | Value |
|---|---|
| Return on Equity (ROE TTM) | 33.62% |
| Return on Assets (ROA TTM) | 8.26% |
| Debt/Equity (MRQ) | 0.58x |
| Total Cash (MRQ) | $18.56 Billion |
| Total Debt (MRQ) | $45.80 Billion |
| Current Ratio (MRQ) | 1.07x |
| Quick Ratio (MRQ) | 0.71x |
| Operating Cash Flow (TTM) | $24.20 Billion |
| Levered Free Cash Flow (TTM) | $12.01 Billion |
The company’s Return on Equity (ROE) of 33.62% and Return on Assets (ROA) of 8.26% are particularly impressive. These figures reflect a highly efficient use of capital, which is a hallmark of well-managed, often fast-growing firms. It tells us that JNJ is generating significant profits from the equity invested by its shareholders and from its overall asset base.
JNJ’s Debt/Equity ratio of 0.58x, coupled with $45.80 billion in debt and $18.56 billion in cash, indicates a manageable debt load. The company has strategically used debt to fund its operations and growth initiatives without appearing overleveraged. What’s more, its ability to generate $24.20 billion in operating cash flow (TTM) demonstrates that its core business is a steady cash-producing machine, which is a significant strength.
Looking at liquidity, the Current Ratio of 1.07x and Quick Ratio of 0.71x show a solid position, suggesting JNJ can comfortably cover its short-term liabilities. Furthermore, the $12.01 billion in levered free cash flow indicates that the company can still generate substantial cash for its shareholders even after meeting all its financial obligations. These are all positive signs for long-term investors.
JNJ Financial Efficiency Review
Understanding how efficiently Johnson & Johnson manages its assets and operations is crucial. Let’s break down some key efficiency metrics.
| Metric | Value |
|---|---|
| Asset Turnover (TTM) | 0.51x |
| Inventory Turnover (TTM) | 2.21x |
| Receivables Turnover (TTM) | 6.21x |
| Working Capital Turnover (TTM) | 16.54x |
| Current Ratio (MRQ) | 1.07x |
| Days Sales Outstanding | 58.8 |
| Days Inventory Outstanding | 165.2 |
| Cash Conversion Cycle | ~224.0 days (partial) |
| Return on Invested Capital (ROIC TTM) | 23.23% |
Johnson & Johnson’s Asset Turnover of 0.51x suggests that for every dollar of assets, the company generates $0.51 in revenue. This indicates moderate efficiency in utilizing its asset base to drive sales. The Inventory Turnover of 2.21x means JNJ sells and replaces its inventory roughly 2.2 times annually, which translates to about 165.2 Days Inventory Outstanding.
Meanwhile, the Receivables Turnover of 6.21x and 58.8 Days Sales Outstanding reflect adequate efficiency in collecting payments from its customers. The impressive Working Capital Turnover of 16.54x highlights highly efficient use of short-term assets to support sales, further supported by a healthy Current Ratio of 1.07x, signaling adequate liquidity to meet short-term obligations.
The Cash Conversion Cycle of approximately 224.0 days (partial) suggests it takes about 7.5 months for JNJ to convert its investments in inventory and receivables into cash. This extended cycle could potentially put some strain on working capital, and it’s a metric to watch. However, JNJ’s strong Return on Invested Capital (ROIC) of 23.23% indicates robust capital efficiency, showing how effectively the company generates returns from the capital it has invested. Overall, while JNJ demonstrates strong efficiency in many areas, enhancing asset utilization could further boost profitability. It’s always a good idea to compare these figures with industry peers to assess its competitive standing.
JNJ Profitability and Growth Metrics
Let’s dissect Johnson & Johnson’s profitability and growth, which are crucial indicators of its long-term potential.
| Metric | Value |
|---|---|
| Profit Margin (TTM) | 27.26% |
| Operating Margin (TTM) | 30.20% |
| Gross Margin (TTM) | 68.36% |
| EBITDA Margin (TTM) | 34.64% |
| Revenue (TTM) | $92.15 Billion |
| Quarterly Revenue Growth (YoY) | 6.80% |
| Gross Profit (TTM) | $62.99 Billion |
| EBITDA (TTM) | $31.92 Billion |
| Net Income (TTM) | $25.12 Billion |
| Earnings Growth (YoY) | 91.00% |
JNJ’s margin performance shows a solid grasp on cost control and pricing power. The impressive gross margin of 68.36% highlights the company’s success in managing production costs. Furthermore, its operating margin of 30.20% indicates healthy profits from core operations.
An EBITDA margin of 34.64% signals JNJ’s strong ability to generate cash flow from its operations before accounting for financing and tax strategies. All things considered, JNJ manages to retain approximately $27.26 in net profit for every $100 of revenue over the last twelve months. While the business is growing aggressively with a 6.80% year-over-year revenue increase, investors should monitor whether this pace can be sustained without eroding those healthy profit margins.
With $31.92 billion in EBITDA and $62.99 billion in gross profit, JNJ clearly demonstrates significant raw earning power. The $25.12 billion in net income reveals how effectively it converts that power into bottom-line results for shareholders. The company appears to be striking a good balance between pursuing growth and maintaining strong profitability.
However, there’s a noticeable gap between its gross and net margins (68.36% vs. 27.26%). This difference likely stems from substantial operating expenses, interest costs, or taxes, which are important areas for investors to monitor. Moving forward, maintaining steady or improving margins will be critical. JNJ needs to continue defending its pricing power and controlling operating costs to sustain profitability, especially if revenue growth were to moderate.
JNJ Dividends and Shareholder Returns Analysis
For income-focused investors, Johnson & Johnson’s dividend policy is always a key consideration. Let’s break down the details.
Dividend Summary & Investor Implications
Johnson & Johnson currently offers a $5.20 annual dividend per share, which translates to a dividend yield of 2.55%. This means for every $100 invested, shareholders receive approximately $2.55 in dividends annually. It’s worth noting that this yield is currently below the 5-year average of 2.79%. This could indicate either that the stock price has appreciated significantly (thereby reducing the yield relative to the price) or that dividend growth hasn’t quite kept pace with historical trends.
| Metric | Value |
|---|---|
| Dividend Rate | $5.20 |
| Dividend Yield | 2.55% |
| Payout Ratio | 49.08% |
| 5 Year Average Dividend Yield | 2.79% |
| Trailing Dividend Rate | $5.08 |
| Trailing Dividend Yield | 0.03% |
| Ex-Dividend Date | 2025-11-25 |
| Last Split Date | 2001-06-13 |
| Last Split Factor | 2:1 |
Key Observations & Analysis:
- The payout ratio of 49.08% is healthy. This signifies that JNJ uses only about 49% of its earnings to fund its dividends, leaving ample room for future increases or for reinvesting profits back into the business for growth.
- The very low trailing yield of 0.03% suggests a potential data anomaly, perhaps a recent dividend initiation or a special, non-recurring payout that skews the trailing calculation. It warrants further investigation for consistency.
- To receive the next dividend, investors must own the stock before the upcoming ex-dividend date of November 25, 2025.
- The last stock split (2:1 in 2001) is quite old and likely has minimal relevance to the current valuation or dividend strategy.
Investor Takeaway:
- For Income Investors: The dividend appears sustainable given the healthy payout ratio. However, it’s always wise to monitor earnings and cash flow to ensure the payout remains well-supported over the long term.
- For Growth Investors: JNJ strikes a commendable balance between returning capital to shareholders and reinvesting for future growth. This makes it an appealing option for those pursuing a “growth and income” strategy.
- What to Watch For: Keep an eye out for announcements of dividend hikes, which could bring the yield closer to its historical average. Also, significant stock price changes will naturally alter the effective yield.
JNJ Technical Analysis: Bullish but Overheated
Current Price: $203.90 | Trend: Bullish but Overheated
The stock has certainly been on a notable run, gaining +9.05% in just 15 days. However, several technical signals suggest that while the trend is positive, we should approach with caution and avoid chasing this momentum blindly. Let’s break down what the charts are indicating.
Trend Strength – Still Bullish
JNJ is trading comfortably above its key moving averages, which is a strong confirmation that the underlying uptrend remains intact. Specifically, the 20-day Simple Moving Average (SMA) is at $193.17, acting as a crucial immediate dynamic support level. As long as the price holds above this, the bullish momentum could continue. However, a rapid climb can push the stock significantly far from its averages, increasing the risk of a swift pullback.
Momentum Check – Time to Be Cautious
Here’s where the caution comes in: the Relative Strength Index (RSI) is flashing a strong overbought signal at 100.0. Historically, when the RSI moves above 70-75, it often precedes a period of consolidation or a pullback before the next leg up. This doesn’t mean the stock can’t go higher, but it suggests the rally might be stretched. At the same time, the MACD histogram is positive, which confirms that the upward momentum is still in play in the short term.
Trading Strategy:
- Aggressive traders might consider taking partial profits to de-risk.
- Conservative traders should probably wait for the RSI to cool down below 70 before considering new positions.
Bollinger Bands – Testing Key Levels
The stock is currently pressing right against the upper Bollinger Band at $205.87. This often acts as a short-term resistance level. A sustained break above this could signal further upside, but it’s also a point where prices frequently reverse or consolidate.
Volume Trends – Checking for Conviction
Trading volume is currently near its recent average. This provides neutral confirmation of the current price action. Ideally, we’d want to see strong, increasing volume on breakouts and declining volume on pullbacks for robust trend confirmation.
Support & Resistance – The Trading Plan
Understanding these key levels is essential for any trading or investment strategy:
- Resistance: $206.94 (Recent High) – A decisive breakout above this level, especially with strong volume, could propel JNJ higher.
- Support: $193.17 (20-day SMA) – If JNJ breaks below this, expect a test of the next significant support around $180.47.
- Critical Support: $170.68 (200-day SMA) – A drop below $180.47 could trigger a deeper correction towards the long-term 200-day SMA.
Trading Plan Summary:
- ✅ If JNJ holds above $193.17: The bullish trend is likely to continue, with the next target at $206.94.
- ⚠️ If it breaks below $193.17: Expect a dip toward $180.47.
- 🛑 A drop below $180.47: This could signal a deeper correction, potentially heading towards the 200-day SMA at $170.68.
Final Verdict – Should You Buy, Hold, or Sell JNJ?
- Short-Term Traders: Exercise caution. The RSI is significantly overbought at 100.0, and volume isn’t exceptionally strong. Consider taking partial profits near $206.94 and waiting for a more favorable entry point closer to the 20-day SMA ($193.17).
- Long-Term Investors: The long-term uptrend for JNJ remains valid as long as the price stays above the 200-day SMA ($170.68). A pullback to the 50-day SMA ($191.54) area could present a safer, more attractive buying opportunity for building a long-term position.
- New Buyers: It’s generally wise to avoid chasing this current rally. Wait for either a confirmed breakout above $206.94 with strong volume, or a pullback to the $193.17 area, which would offer a much better risk/reward entry.
Bottom Line: The technical indicators suggest that the current rally in JNJ stock might be losing some steam in the short term. While the long-term trend remains bullish, a correction or consolidation phase seems plausible before the next significant move. Trade carefully, always waiting for clear confirmation at these key technical levels.
JNJ Historical Performance Analysis
Let’s review Johnson & Johnson’s recent trading history to understand its short-term price movements and volume trends.
Analyzing the last 15 trading days, specifically from November 07, 2025, to November 21, 2025, JNJ’s stock posted a return of +9.29%. This indicates a strong upward movement in the very recent past. During this period, the stock traded within a range of $185.12 to $206.94, with an average daily volume of 9,452,047 shares.
JNJ Recent Trading Data
Here’s a detailed look at JNJ’s daily trading activity for the most recent period:
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| 2025-11-21 | $203.96 | $206.94 | $202.99 | $203.90 | 13,175,700 |
| 2025-11-20 | $202.00 | $204.51 | $201.57 | $203.07 | 10,612,600 |
| 2025-11-19 | $200.00 | $203.48 | $199.38 | $202.51 | 14,690,800 |
| 2025-11-18 | $199.01 | $200.30 | $198.53 | $200.00 | 12,468,600 |
| 2025-11-17 | $196.96 | $200.28 | $195.90 | $199.58 | 13,257,000 |
| 2025-11-16 | $195.00 | $197.18 | $193.55 | $195.93 | 8,824,800 |
| 2025-11-15 | $195.00 | $197.18 | $193.55 | $195.93 | 8,824,800 |
| 2025-11-14 | $195.00 | $197.18 | $193.55 | $195.93 | 8,824,800 |
| 2025-11-13 | $194.21 | $196.00 | $193.45 | $195.25 | 8,631,600 |
| 2025-11-12 | $193.36 | $195.55 | $193.07 | $194.39 | 8,803,000 |
| 2025-11-11 | $189.39 | $193.92 | $189.05 | $193.83 | 7,465,600 |
| 2025-11-10 | $186.00 | $188.42 | $185.12 | $188.41 | 5,323,800 |
| 2025-11-09 | $187.74 | $188.35 | $185.70 | $186.57 | 6,959,200 |
| 2025-11-08 | $187.74 | $188.35 | $185.70 | $186.57 | 6,959,200 |
| 2025-11-07 | $187.74 | $188.35 | $185.70 | $186.57 | 6,959,200 |
JNJ Stock Price Statistics and Volatility
Let’s delve into some key stock price statistics for JNJ to understand its historical movements and volatility profile.
| Metric | Value |
|---|---|
| 52 Week High | $206.94 |
| 52 Week Low | $140.68 |
| 50 Day MA | $187.75 |
| 200 Day MA | $167.81 |
| Beta | 0.36x |
| Volatility (30d Ann.) | 14.2% |
Looking at the price range over the past year, JNJ has seen a high of $206.94 and a low of $140.68. This notable difference indicates that the stock has experienced significant price swings over the last twelve months.
Currently, the 50-day moving average sits at $187.75, which is above the 200-day moving average of $167.81. This configuration, often referred to as a “golden cross,” is generally viewed as a bullish signal, suggesting positive long-term momentum is building.
With a Beta of 0.36x, JNJ tends to be less volatile than the broader market, moving about 64% less than the overall market. Combined with a low 30-day annualized volatility of 14.2%, it’s clear this stock doesn’t experience the wild, unpredictable swings of some other assets. For investors, this generally means a more stable ride. These indicators are crucial when you’re deciding on position sizing or the optimal timing for your entry, especially if your portfolio aims to balance stability with growth exposure.
JNJ Quarterly Earnings Performance Overview
Examining Johnson & Johnson’s recent quarterly performance gives us a fresh look at the company’s operational health and growth trajectory.
| Metric | Value |
|---|---|
| QoQ Revenue Growth | +1.1% |
| QoQ Net Income Growth | -7.0% |
| YoY Revenue Growth | +6.8% |
JNJ’s latest reported quarter shows revenue of $23.99 billion and net income of $5.15 billion. While the quarter-over-quarter revenue change was a modest +1.1%, the year-over-year revenue growth stands at a more robust +6.8%. This indicates a solid trend in top-line expansion over a longer period.
Recent Quarterly Results (Last 4 Quarters)
Here’s a breakdown of Johnson & Johnson’s performance over the past four quarters:
| Quarter | Revenue | Net Income | EPS | Gross Margin |
|---|---|---|---|---|
| 2025-Q3 | $23.99 Billion | $5.15 Billion | 2.12x | 69.6% |
| 2025-Q2 | $23.74 Billion | $5.54 Billion | 2.29x | 67.9% |
| 2025-Q1 | $21.89 Billion | $11.00 Billion | 4.54x | 66.4% |
| 2024-Q4 | $22.52 Billion | $3.43 Billion | 1.41x | 68.3% |
Growth Metrics: A Closer Look
While year-over-year revenue growth is strong, the quarter-over-quarter net income growth saw a dip of -7.0%. This might warrant a closer look at factors impacting profitability in the most recent quarter, even as the overall revenue trend remains positive.
Upcoming Earnings
Investors should mark their calendars for the next earnings report, scheduled for January 21, 2026. The previous earnings call was on October 14, 2025, at 06:00 PM ET. These events are crucial for understanding management’s outlook and any new developments.
JNJ Short Selling Information
Understanding short interest can provide valuable insights into market sentiment and potential price movements. Let’s look at JNJ’s short selling data.
| Metric | Value |
|---|---|
| Shares Short | 20 Million |
| Short Ratio (Days To Cover) | 2.30x |
| Short % of Float | 0.81% |
| Shares Short (Prior Month) | 18 Million |
| Short Date | 2025-10-31 |
Currently, there are 20 million shares of JNJ that have been sold short. The short ratio, also known as “days to cover,” stands at 2.3x. This means that, based on the stock’s recent average trading volume, it would take approximately 2 days for all short positions to be covered. This relatively low number suggests that short sellers don’t currently exert significant control over JNJ’s price, and the risk of a prolonged “short squeeze” is quite low.
With only 0.81% of the public float sold short, a very small percentage of available shares are being bet against. This indicates a general lack of strong bearish sentiment among investors. While this level has recently increased from 18 million shares shorted last month, it still remains low. Generally, when short interest is low, the market tends to feel more confident, and the risks of sudden price swings due to short-covering activities are reduced.
JNJ Risk Analysis: What Investors Should Know
Every investment comes with risks, and JNJ is no exception. Let’s examine some key risk metrics to provide a clearer picture of its risk profile.
| Metric | Value |
|---|---|
| Volatility (Annualized) | 15.2% |
| Value at Risk (5%) | -1.35% |
| Value at Risk (1%) | -2.81% |
| Sharpe Ratio | 0.38x |
| Sortino Ratio | 0.50x |
| Maximum Drawdown | -27.37% |
| Skewness | -0.24x |
| Kurtosis | 15.48x |
JNJ’s risk profile shows moderate volatility, with an annualized volatility of 15.2%. This figure indicates a moderate level of investment risk, suggesting that while the stock moves, its swings aren’t as extreme as those of highly volatile assets.
The Sharpe ratio of 0.38x provides an insight into its risk-adjusted returns, suggesting a mixed performance relative to the risk taken. Meanwhile, the maximum drawdown of -27.37% indicates the largest percentage drop the stock has experienced from a peak to a trough during a specific period. This offers a sense of the potential downside risk during adverse market conditions.
The Value at Risk (VaR) at a 5% confidence level shows a potential loss of -1.35% in the worst 5% of scenarios. At a 1% confidence level, the potential loss increases to -2.81%. These VaR figures help quantify potential losses over a specific timeframe under normal market conditions. The Sortino ratio of 0.50x, which specifically focuses on downside risk, offers additional insight into how effectively JNJ generates returns for each unit of bad risk. Investors should carefully weigh these risk metrics against their personal risk tolerance and overall investment objectives.
JNJ Sentiment Analysis: What the Market is Saying
Understanding overall market sentiment can be a powerful tool for investors. Let’s see what the various sentiment indicators are telling us about JNJ.
| Metric | Value |
|---|---|
| Composite Sentiment Score | 0.22x |
| Sentiment Classification | Positive |
| Sentiment Confidence | 37.4% |
| News Sentiment | Neutral (-0.02x) |
| Analyst Sentiment | Positive (0.40x) |
| Options Sentiment | Negative (-0.12x) |
| Put/Call Ratio | 0.56x |
Current market sentiment analysis for JNJ reveals a cautiously positive outlook, with a composite sentiment score of 0.22x and a confidence level of 37.4%. This overall positive sentiment is derived from a blend of data sources, including recent news coverage, analyst recommendations, and activity in the options market.
Breaking down these components, news analysis shows a largely Neutral sentiment (-0.02x), indicating that recent headlines haven’t significantly swayed opinion one way or the other. However, the analyst consensus is distinctly Positive (0.40x), suggesting that financial professionals hold a favorable view of the stock. Interestingly, options market sentiment reflects a slightly Negative stance (-0.12x), which might imply some hedging or bearish bets among options traders.
This overall weak positive sentiment signal should be carefully considered alongside both fundamental and technical analysis to develop a comprehensive investment perspective. It’s a reminder that while some aspects are positive, there isn’t overwhelming conviction across all sentiment indicators.
JNJ Peer Comparison: How Does it Stack Up?
To truly understand Johnson & Johnson’s position, we need to compare it against its industry peers. Let’s see how JNJ measures up against other pharmaceutical giants like Eli Lilly (LLY), Merck & Co. (MRK), and Pfizer (PFE).
| Metric | JNJ | LLY | MRK | PFE |
|---|---|---|---|---|
| Market Cap | $491.26B | $949.98B | $244.18B | $142.37B |
| P/E Ratio | 19.68 | 51.82 | 12.93 | 14.56 |
| Revenue Growth | 6.80% | 53.90% | 3.70% | -5.90% |
| Net Margin | 27.26% | 30.99% | 29.63% | 15.65% |
| EPS | 10.36 | 20.45 | 7.56 | 1.72 |
| ROE | 33.62% | 96.47% | 39.49% | 10.60% |
| Debt-to-Equity | 57.77 | 179 | 79.71 | 66.53 |
| Dividend Yield | 2.55% | 57.00% | 3.48% | 6.87% |
| 52-Week Range | 137.37 – 206.94 | 621.50 – 1066.65 | 71.87 – 101.32 | 19.83 – 27.21 |
JNJ’s $491.26 billion market cap positions it as a significant player, trailing Eli Lilly (LLY) at $949.98 billion but comfortably ahead of Merck (MRK) at $244.18 billion and Pfizer (PFE) at $142.37 billion. When it comes to valuation, JNJ’s conservative P/E ratio of 19.68 suggests a more value-oriented pricing compared to LLY’s premium P/E of 51.82. In contrast, MRK (P/E 12.93) and PFE (P/E 14.56) trade at lower multiples, often reflecting more mature or slower-growth business profiles.
In terms of growth, JNJ shows a modest 6.80% revenue expansion, which is solid, but LLY demonstrates significantly stronger momentum with 53.90%. However, JNJ’s robust 27.26% net margin highlights strong profitability, comparable to LLY’s 30.99% and MRK’s 29.63%.
JNJ’s exceptional 33.62% Return on Equity (ROE) indicates highly efficient use of shareholder capital. While LLY’s ROE is even higher, JNJ’s figure is still very impressive. With a Debt-to-Equity ratio of 57.77, JNJ maintains moderate leverage, especially when compared to LLY’s higher leverage at 179. Finally, JNJ’s 2.55% dividend yield provides a respectable income stream to shareholders, though LLY, MRK, and PFE offer higher yields in this comparison.
Also Read –
-
Eli Lilly and Company (LLY) Stock Analysis: Price Forecast, Technicals & Investment Outlook
-
Visa Inc. (V) Stock Analysis: Price Forecast, Technicals & Investment Outlook
-
Walmart Inc. (WMT) Stock Analysis: Price Forecast, Technicals & Investment Outlook
-
JPMorgan Chase & Co. (JPM) Stock Analysis: Price Forecast, Technicals & Investment Outlook
JNJ Insider Transactions (Last 3 Months)
Insider transactions can offer valuable clues about how those closest to the company view its prospects. Let’s analyze JNJ’s insider activity over the last three months.
The insider transaction data reveals a mixed pattern, with 6 buys and 6 sells over the past three months. This suggests a somewhat balanced sentiment among insiders. When we focus specifically on discretionary open-market activity, there were 2 market sales compared to 0 market purchases, indicating that insiders have been actively reducing their positions through direct sales.
Additionally, there were 6 option exercises. These can indicate either confidence in future price appreciation (as insiders convert options to shares) or routine portfolio management, so they require careful interpretation. Transaction prices show some consistency, with sales averaging $153.86 and purchases averaging $151.61, suggesting insiders are transacting around current market levels. The recent market transactions lean towards selling, with insiders continuing to reduce their near-term holdings. This mixed activity pattern is quite typical for established companies like JNJ, where insiders balance personal financial planning with maintaining confidence in the business fundamentals.
| Insider Name | Type | Shares Changed | Price | Shares After | Transaction Date | Filing Date |
|---|---|---|---|---|---|---|
| REED JOHN C | SELL (Exercise) [M] | -21,721 | $157.92 | 43,442 | 2025-10-17 | 2025-10-20 |
| REED JOHN C | SELL (Sale) [S] | -21,721 | $192.71 | 10,658 | 2025-10-17 | 2025-10-20 |
| REED JOHN C | BUY (Exercise) [M] | +21,721 | $157.92 | 32,379 | 2025-10-17 | 2025-10-20 |
| Woods Eugene A. | BUY (Award) [A] | +211 | $178.07 | 4,841 | 2025-09-09 | 2025-09-11 |
| Pinto Daniel E | BUY (Award) [A] | +175 | $178.07 | 175 | 2025-09-09 | 2025-09-11 |
| HEWSON MARILLYN A | BUY (Award) [A] | +281 | $178.07 | 13,817 | 2025-09-09 | 2025-09-11 |
| Taubert Jennifer L | SELL (Sale) [S] | -56,471 | $177.81 | 178,013 | 2025-09-04 | 2025-09-05 |
| Taubert Jennifer L | BUY (Exercise) [M] | +56,471 | $101.87 | 234,484 | 2025-09-04 | 2025-09-05 |
| Forminard Elizabeth | SELL (Tax Payment) [F] | -9,570 | $177.20 | 12,853 | 2025-08-29 | 2025-09-03 |
| Forminard Elizabeth | BUY (Exercise) [M] | +11,521 | $115.67 | 22,423 | 2025-08-29 | 2025-09-03 |
JNJ Key Risk Factors for Investors
Potential investors in Johnson & Johnson (JNJ) should be aware of several risk factors that could impact the stock’s performance. While this list highlights key considerations based on current data and market dynamics, it’s not exhaustive.
- ⚠️ RSI (100.0) is high (>70): This indicates potential overbought conditions, suggesting the stock may be due for a pullback or consolidation in the short term. Chasing the rally at this point could expose investors to increased risk.
- ⚠️ General market fluctuations and economic conditions: Like all stocks, JNJ is susceptible to broader market downturns and shifts in economic sentiment. The Healthcare sector, while often defensive, is not immune to these wider macroeconomic forces.
- ⚠️ Intense competition in the Drug Manufacturers – General industry: JNJ operates in a highly competitive landscape. New entrants, innovative breakthroughs from rivals, and pricing pressures can impact market share and profitability.
- ⚠️ Significant debt load ($45.80 Billion): While manageable, JNJ’s substantial debt could become a headwind, particularly in an environment of rising interest rates, increasing financing costs.
- ⚠️ Regulatory and legal risks: The pharmaceutical industry is heavily regulated. Changes in healthcare policy, drug approvals, and ongoing litigation (e.g., product liability) can pose significant financial and reputational risks.
JNJ Analyst Insights and Consensus
What do professional analysts covering Johnson & Johnson think about its future? Let’s summarize their collective view.
| Metric | Value |
|---|---|
| Recommendation | Buy |
| Mean Target Price | $200.82 |
| High Target Price | $230.00 |
| Low Target Price | $155.00 |
| Number of Analyst Opinions | 24 |
The consensus recommendation for JNJ is a clear ‘Buy’, based on the opinions of 24 analysts. This indicates a generally favorable outlook from Wall Street professionals.
The mean price target stands at $200.82. Individual analyst targets range widely, from a low of $155.00 to a high of $230.00. When comparing the average target of $200.82 to the current price of $203.90, it suggests a potential -1.5% downside. This provides a useful gauge of Wall Street’s sentiment regarding the stock’s near-term potential, implying that while they like the stock, some believe it might be slightly overvalued at its current level.
JNJ Recent News and Developments
Staying updated on the latest news is crucial for understanding potential catalysts and market reactions affecting Johnson & Johnson. Here are some recent headlines that could influence investor sentiment:
- Jim Cramer on Kenvue: “I Think It is a Good Situation, Not a Bad One” – Publisher: Insider Monkey (Published: 2025-11-22T07:29:53Z)
- How Recent Developments Are Rewriting the Story for Johnson & Johnson – Publisher: Simply Wall St. (Published: 2025-11-22T03:15:03Z)
- Contineum’s MS drug falls short in Phase II trial – Publisher: Clinical Trials Arena (Published: 2025-11-21T18:32:26Z)
- 1 Reason Why Shares of Johnson & Johnson Are Surging This Month – Publisher: Motley Fool (Published: 2025-11-21T17:43:10Z)
- Eli Lilly Reaches $1 Trillion Market Cap on Booming Weight-Loss Drugs – Publisher: The Wall Street Journal (Published: 2025-11-21T15:29:00Z)
JNJ Conclusion and Outlook
Let’s synthesize all the information we’ve gathered on Johnson & Johnson (JNJ) to provide a comprehensive outlook for investors.
Short-Term Technical Snapshot
- Overall Technical Sentiment: Neutral
- Price Trend vs MAs: Bullish (above SMA50/200)
- Momentum (RSI): Overbought (100.0)
- Support / Resistance (30d): ~$184.66 / ~$206.94
The technical picture for JNJ in the short term is a bit mixed. While the price is showing a strong bullish trend by staying above its key moving averages, the extremely high RSI of 100.0 indicates that the stock is currently overbought. This suggests a potential for a near-term pullback or consolidation, even within an overall uptrend. Traders should be cautious.
Longer-Term Fundamental & Forecast Outlook
- 1-Year Avg. Forecast: ~-6.2% avg. change to ≈$191.21
- Fundamental Health: Assessment Incomplete (ROE: 33.62%, D/E: 0.58x)
- Valuation Snapshot: Appears Moderate (Fwd P/E: 19.24x)
- Recent Growth (YoY): Positive (Revenue: 6.80%, Earnings: 91.00%)
- Analyst Consensus: Buy (Target: $200.82)
From a longer-term perspective, JNJ’s fundamentals appear solid, boasting strong ROE and a manageable debt-to-equity ratio. The company has demonstrated positive recent growth in both revenue and earnings. Its forward P/E suggests a moderate valuation. However, our 1-year forecast model projects a potential downside of -6.2% to around $191.21. Interestingly, the analyst consensus is still a ‘Buy’ with a target of $200.82, which is slightly above our model’s average forecast.
Overall Assessment & Outlook for JNJ Stock
Overall, JNJ presents a compelling story of a fundamentally healthy company with a strong market position. The technical setup points to a strong uptrend, but the overbought RSI signals caution for the immediate short term. While the 1-year forecast model suggests a potential modest downside, this contrasts with a positive analyst consensus. Johnson & Johnson’s moderate valuation and strong recent growth figures are attractive.
Investors should carefully consider these points relative to their individual investment horizon and risk tolerance. It’s crucial to weigh the identified risks, such as the high RSI and competitive pressures, against the company’s robust financial health and growth trajectory.
Frequently Asked Questions About JNJ Stock
What is the JNJ stock price prediction for the next year (2025-2026)?
Based on current models, the average 1-year price forecast for JNJ is approximately $191.21. This represents a potential -6.2% change from the recent price of $203.90. Remember, this is a model-driven estimate, not a guarantee, and actual prices will fluctuate based on numerous market factors.
Will JNJ stock go up or down?
The 1-year forecast model suggests the price might see modest losses on average (-6.2% potential). However, the short-term direction is highly uncertain and heavily influenced by prevailing market sentiment (currently ‘Neutral’), breaking news, and overall economic conditions. Technical indicators like the RSI (currently 100.0) can provide clues for near-term direction, suggesting caution due to overbought conditions.
Is JNJ stock a good investment right now?
Deciding if JNJ is a “good buy” involves balancing several elements: its ‘Neutral’ technicals, a -6.2% forecast potential, and its overall financial health. Technically, the RSI indicates overbought conditions (RSI: 100.0), suggesting caution or potential for a pullback. Weigh the company’s solid valuation, stability, and growth against identified risk factors such as high competition and a substantial debt load. Always align your decision with your own investment goals and risk profile.
How volatile is JNJ stock?
Based on the recent 30-day price action, JNJ’s annualized volatility is approximately 14.2%. This level is considered moderate, indicating a reasonable degree of price fluctuation. This aligns with its Beta of 0.36x, suggesting it tends to be less volatile than the broader market. Moderate volatility means potential for gains, but also requires careful risk management.
What is JNJ’s P/E ratio and what does it mean?
JNJ’s Trailing P/E ratio (based on past earnings) is 19.68x, which is considered moderate. The Forward P/E (based on expected earnings) is 19.24x. A P/E ratio indicates how much investors are paying per dollar of earnings. You should compare this to industry peers and historical levels. A moderate P/E isn’t necessarily a bad thing, especially if it’s supported by strong growth prospects.
What are the key upcoming events for JNJ?
A key upcoming event for income investors is the ex-dividend date on November 25, 2025. Beyond this, investors should closely monitor macroeconomic shifts, any competitive actions within the pharmaceutical and medical technology sectors, and major corporate announcements regarding product pipelines or strategic partnerships.
What does JNJ’s liquidity position reveal about its financial health?
JNJ’s financial health includes an adequate Current Ratio of 1.07x, suggesting it can cover its short-term liabilities. More importantly, its robust operating cash flow of $24.20 billion and levered free cash flow of $12.01 billion provide a significant buffer. These strong cash flows are critical factors in its ability to fund operations, manage debt, and return value to shareholders.
Pingback: Hims & Hers Health, Inc. (HIMS) Stock Analysis: Comprehensive Investment Guide & Market Insights - Stockdunia